129 related articles for article (PubMed ID: 28639950)
1. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
[TBL] [Abstract][Full Text] [Related]
3. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.
Zekri A; Ghaffari SH; Ghanizadeh-Vesali S; Yaghmaie M; Salmaninejad A; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Tumour Biol; 2015 Feb; 36(2):623-32. PubMed ID: 25277659
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
5. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
7. The Potential Contribution of microRNAs in Anti-cancer Effects of Aurora Kinase Inhibitor (AZD1152-HQPA).
Zekri A; Mesbahi Y; Boustanipour E; Sadr Z; Ghaffari SH
J Mol Neurosci; 2018 Aug; 65(4):444-455. PubMed ID: 30051358
[TBL] [Abstract][Full Text] [Related]
8. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
9. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
11. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
[TBL] [Abstract][Full Text] [Related]
13. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
Tomita M; Tanaka Y; Mori N
Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
Sarvagalla S; Hsieh HP; Coumar MS
Expert Opin Ther Pat; 2016 Jul; 26(7):751-5. PubMed ID: 27167102
[TBL] [Abstract][Full Text] [Related]
15. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
16. Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny.
Wiedemuth R; Klink B; Fujiwara M; Schröck E; Tatsuka M; Schackert G; Temme A
Carcinogenesis; 2016 Oct; 37(10):993-1003. PubMed ID: 27515963
[TBL] [Abstract][Full Text] [Related]
17. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Marchetti S; Pluim D; van Eijndhoven M; van Tellingen O; Mazzanti R; Beijnen JH; Schellens JH
Invest New Drugs; 2013 Oct; 31(5):1125-35. PubMed ID: 23315030
[TBL] [Abstract][Full Text] [Related]
18. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.
Ikezoe T; Yang J; Nishioka C; Yokoyama A
Int J Hematol; 2010 Jan; 91(1):69-77. PubMed ID: 20013323
[TBL] [Abstract][Full Text] [Related]
19. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
20. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]